Skip to Content

Wadih Arap, MD, PhD

Present Title & Affiliation

Primary Appointment

Stringer Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

As a matter of record, I have a long-standing collaboration and have jointly led a research laboratory with Dr. Pasqualini since October 1999 (please note that we are husband-and-wife).  Since our arrival at MDACC, we have published over 130 original peer-reviewed research manuscripts and.  Our research group currently includes several graduate or M.D./Ph.D. students, postdoctoral fellows, faculty (assistant and associate professors), research technicians, and administrative staff members.  Our central working hypothesis is that differential protein expression in the human vascular endothelium associated with normal or diseased tissues offers the potential for developing novel diagnostic, imaging, and therapeutic strategies. In essence, our research program uses combinatorial library selection (peptide- and antibody-based) to discover, validate, and exploit the biochemical diversity of endothelial (vascular) cell surfaces towards a new targeted pharmacology.  Such technologies may lead to the development of ligand-directed therapeutic and imaging agents. Of note, in 2009, the FDA approved a First-in-Human study for our first Investigational New Drug (IND). Several patients have already been enrolled in this MDACC-sponsored clinical trial.  A second IND was filed mid-November 2010, two other targeted-therapeutics are in pre-IND stage. Several others are evolving in pre-clinical laboratory phase. Long-term, the broader vision of our research is to construct a large-scale map of receptors in the human vasculature (termed human vascular zip codes) towards a new ligand-directed pharmacology.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 0018-1
P.O. Box 301439
Houston, TX 77230-1439
Room Number: T7.3904

Education & Training

Degree-Granting Education

1996 Stanford University and Ludwig Institute for Cancer Research, La Jolla, CA, PHD, Cancer Biology
1983 University of São Paulo Medical School, São Paulo, Brazil, MD, Medicine

Postgraduate Training

1997-1999 Research Fellowship, Cell Biology and Biochemistry, The Burnham Institute, La Jolla, CA
1987-1991 Clinical Fellowship, Medical Oncology and Hematology Fellow, PGY4-PGY7, Memorial Sloan-Kettering Cancer Center, New York, NY
1984-1986 Clinical Residency, Internal Medicine Resident, PGY1-PGY3, University Hospital, University of São Paulo Medical School, São Paulo, Brazil

Experience/Service

Academic Appointments

Deputy Chairman, David H. Koch Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2012
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-2003
Staff Scientist, The Burnham Institute, La Jolla, CA, 1998-1999

Administrative Appointments/Responsibilities

Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004-2012

Endowed Positions

Hubert L. and Olive Stringer Professorship for Cancer Treatment and Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005-present

Honors and Awards

2009 Edith and Peter O'Donnell Award, The Academy of Medicine, Engineering and Science of Texas
2006 Marcus Foundation Award
2006 Recipient of the 2006 Fellows of the MD Anderson Research Trust Award
2006 The 2006 Robert M. Chamberlain Distinguished Mentor Award Nominee
2003 Golfers Against Cancer Foundation Award
2003 The American Society for Clinical Investigation, Inducted ("Young Turk")
2002 The Randall-Downey Foundation Award
2001 The V Foundation Award on Translational Cancer Research
2000-2011 The Gillson-Longenbaugh Foundation Awards
2000 Angel Works Award
1997-2002 CaPCURE Award
1990-1993 Ph.D. Fellowship Award, Brazilian National Council for Research (CNPq)
1990 Clinical Scholar in Biomedical Research, Michael and Ethel Cohen Fellowship Fund, Memorial Hospital, Memorial Sloan-Kettering Cancer Center
1989 Charles A. Dana Foundation Fellowship Award, Memorial Hospital, Memorial Sloan-Kettering Cancer Center
1988 Clinical Scholars Research Training Fellowship Award, Frederick R. Adler Fellowship in Biomedical Research, Memorial Hospital, Memorial Sloan-Kettering Cancer Center
1987-1990 Medical Career Development Award, Brazilian National Council for Research (CNPq)
1984 Highest score In-Service Qualifying Exam, Residency in Internal Medicine (over 30 resident examinees), University of Sao Paulo Medical School
1983 Highest Score, Medical Proficiency Exam, for internship admittance (over 3,000 intern examinees), University of Sao Paulo Medical School

Selected Publications

Peer-Reviewed Original Research Articles
1. Rotolo J, Stancevic B, Zhang J, Hua G, Fuller J, Yin X, Haimovitz-Friedman A, Kim K, Qian M, Cardó-Vila M, Fuks Z, Pasqualini R, Arap W, Kolesnick R. Anti-ceramide antibody prevents the radiation GI syndrome in mice. J Clin Invest 122(5), 5/2012. e-Pub 4/2012. PMID: 22466649.
2. Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, Koivunen E, Sidman RL, Arap W, Pasqualini R. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci U S A 109(5):1637-42, 1/2012. PMID: 22307623.
3. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. Targeting white adipose tissue in obese monkeys results in weight loss and improved insulin resistance. Sci Transl Med 3(108):108ra112, 11/2011.
4. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu S-M, Botz GH, Wallace MJ, O'Connell D, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do K-A, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 11/2011.
5. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365(10):892-900, 9/2011. PMID: 21899450.
6. Carraro DM, Ferreira EN, de Campos-Molina G, Puga RD, Abrantes EF, Trape AP, Eckhardt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani H, Dias-Neto E, Brentani RR. Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines. PLoS ONE 6(6):e21022, 7/2011. PMID: 21822460.
7. Binder M, Müller F, Jackst A, Léchenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 117(9):1891-900, 5/2011. PMID: 21509766.
8. Polf JC, Bronk LF, Driessen WHP, Arap W, Pasqualini P, Gillin M. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. Appl Phys Lett 98(19):193702, 5/2011. PMID: 21915155.
9. Moeller BJ, Sidman RL, Pasqualini R, Arap W. Discovery of DNA repair inhibitors by combinatorial library profiling. Cancer Res 71(5):1816-24, 3/2011. PMID: 21343400.
10. Gesteira TF, Coulson-Thomas VJ, Taunay-Rodrigues A, Oliveira V, Thacker BE, Juliano MA, Pasqualini R, Arap W, Tersariol IL, Nader HB, Esko JD, Pinhal MA.. Inhibitory peptides of the sulfotransferase domain of the heparan sulfate enzyme, N-deacetylase-N-sulfotransferase-1. J Biol Chem 286(7):5338-46, 2/2011. PMID: 20129923.
11. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev, 2/2011. PMID: 21287572.
12. Staquicini, FI, Ozawa MG, Moya CA, Driessen WHP, Barbu EM, Nishimori H, Soghomonyan S, Flores LG II, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Hook M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W. Systematic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 121(1):161-73, 1/2011. PMID: 21183793.
13. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117(3):920-7, 1/2011. PMID: 21063027.
14. Li J, Gu X, Ma Y, Calicchio ML, Kong D, Teng YD, Yu L, Crain AM, Vartanian TK, Pasqualini R, Arap W, Libermann TA, Snyder EY, Sidman RL. Nna1 mediates purkinje cell dendritic development via lysyl oxidase propeptide and NF-кB signaling. Neuron 68(1):45-60, 10/2010.
15. Staquicini FI, Sidman RL, Arap W, Pasqualini R. Phage display technology for stem cell delivery and systemic therapy. Adv Drug Deliv Rev 62(12):1213-6, 9/2010. PMID: 20932865.
16. Staquicini FI, Moeller BJ, Arap W, Pasqualini R. Combinatorial vascular targeting in translational medicine. Proteomics Clin Appl 4(6-7):626-32, 7/2010. PMID: 21137081.
17. Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 45(1):66-73, 7/2010. PMID: 20346382.
18. Edwards JK, Pasqualini R, Arap W, Calin GA. MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases. J Cardiovasc Transl Res 3(3):271-9, 6/2010. PMID: 20560048.
19. Souza GR, Molina JR, Raphael RM, Ozawa MG, Stark DJ, Levin CS, Bronk LF, Ananta JS, Mandelin J, Georgescu MM, Bankson JA, Gelovani JG, Killian TC, Arap W, Pasqualini R. Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol 5(4):291-6, 4/2010. PMID: 20228788.
20. Cardó-Vila M, Giordano RJ, Sidman RL, Fan Z, Mendelsohn J, Arap W, Pasqualini R. From combinatorial peptide selection to drug prototype: (II) targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A 107(11):5118-23, 3/2010. PMID: 20190183.
21. Giordano RJ, Cardó-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawk DH, Valente AP, Almeida FCL, Nör JE, Sidman RL, Pasqualini R, Arap W. From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci U S A 107(11):5112-7, 3/2010. PMID: 20190181.
22. Weaver MS, Workman G, Cardó-Vila M, Arap W, Pasqualini R, Sage EH. Processing of the matricellular protein hevin in mouse brain is dependent on ADAMTS4. J Biol Chem 285(8):5868-77, 2/2010. PMID: 20018883.
23. Ardelt PU, Kneitz B, Adam P, Reiss C, Kocot A, Fensterle J, Chen L, Pasqualini R, Arap W, Gerharz EW, Riedmiller H. Reactive antibodies against bacillus calmette-guerin heat shock protein-65 potentially predict the outcome of immunotherapy for high grade transitional cell carcinoma of the bladder. Cancer 116(3):600-9, 2/2010. PMID: 19957324.
24. Ozawa MG, Cardó-Vila M, Mintz PJ, Arap W, Pasqualini R. Cracking the code of compartment-specific dual functionality proteins in cancer: the case for CRKL. Cell Cycle 9(1):8-9, 1/2010. PMID: 20228788.
25. Dias-Neto E, Nunes DN, Giordano, RJ, Sun J, Botz GH, Yang K, Setubal JC, Pasqualini R, Arap W. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One 4(12):e8338, 12/2009.
26. Stefanidakis M, Karjalainen K, Jaalouk DE, Gahmberg CG, O'Brien S, Pasqualini R, Arap W, Koivunen EA. Role of leukemia cell invadosome in extramedullary infiltration. Blood 114(14):3008-17, 10/2009. PMID: 19636064.
27. Jonasch E, Wood C, Matin S, Tu SM, Pagliaro L, Corn P, Aparicio A, Tamboli P, Millikan R, Wang X, Araujo J, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
28. Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, Hajitou A. A heterotypic bystander effect for tumor cell kiling after AAVP-mediated vascular-targeted suicide gene transfer. Mol Cancer Ther 8(8):2383-91, 8/2009. PMID: 19671758.
29. Giordano RJ, Edwards JK, Tuder RM, Arap W, Pasqualini R. Combinatorial ligand-directed lung targeting. Proc Am Thorac Soc 6(5):411-5, 8/2009. PMID: 19687212.
30. Moeller BJ, Pasqualini R, Arap W. Targeting cancer-specific synthetic lethality in double-strand DNA break repair. Cell Cycle 8(12):1872-6, 6/2009. PMID: 19440052.
31. Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL, Pasqualini R, Arap W, Kolonin MG. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Can Res 69(12):5259-66, 6/2009. PMID: 19491274.
32. Mandelin J, Lin ECK, Hu DD, Knowles SK, Do KA, Wang Xuemei, Sage EH, Smith JW, Arap W, Pasqualini R. Extracellular and Intracellular Mechanisms Mediating Metastatic Activity of Exogenous Osteopontin. Cancer 115(8):1753-64, 4/2009. PMID: 19224553.
33. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, LeBlanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE 4(3):e4972, 3/2009. PMID: 19330034.
34. Marchiò S, Pasqualini R, Arap W. Targeting the extracellular signature of metastatic colorectal cancers. Expert Opin Ther Targets 13(3):363-79, 3/2009. PMID: 19236157.
35. Lewis VO, Ozawa MG, Deavers MT, Wang G, Shintani T, Arap W, Pasqualini R. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models and human tumor samples. Cancer Res 69(5):1995-9, 3/2009. PMID: 19244100.
36. Mintz PJ, Cardó-Vila M, Ozawa MG, Hajitou A, Rangel R, Guzman-Rojas L, Christianson DR, Arap MA, Giordano RJ, Souza GR, Easley J, Salameh A, Oliviero S, Brentani RR, Koivunen E, Arap W, Pasqualini R. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc Natl Acad Sci U S A 106(7):2182-7, 2/2009. PMID: 19168626.
37. Staquicini FI, Dias-Neto E, Li J, Snyder EY, Sidman RL, Pasqualini R, Arap W. Discovery of a functional protein complex of netrin-4, laminin {gamma}1 chain, and integrin {alpha}6{beta}1 in mouse neural stem cells. Proc Natl Acad Sci U S A 106(8):2903-8, 2/2009. PMID: 19193855.
38. Staquicini FI, Pasqualini R, Arap W. Ligand-directed profiling: applications to target drug discovery in cancer. Expert Opinion on Drug Discovery (EODC) 4(1):51-9, 1/2009.
39. Tagore DM, Nolte WM, Neveu JM, Rangel R, Guzman-Rojas L, Pasqualini R, Arap W, Lane WS, Saghatelian A. Peptidase substrates via global peptide profiling. Nat Chem Biol 5(1):23-5, 1/2009. PMID: 19011639.
40. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 115(1):128-39, 1/2009. PMID: 19090007.
41. Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 68(22):9112-5, 11/2008. PMID: 1901087.
42. Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valenta AP, Almeida FCL, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R. A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS ONE 3(10):e3452, 10/2008. PMID: 18941632.
43. Nie J, Chang B, Traktuev D, Sun J, March KL, Chan L, Sage EH, Pasqualini R, Arap W, Kolonin MG. Combinatorial peptides identify alpha 5 beta 1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells 26(10):2735-45, 10/2008. PMID: 18583538.
44. Giordano RJ, Lahdenranta J, Zhen L, Chukwueke U, Petrache I, Langley RR, Fidler IJ, Pasqualini R, Tuder RM, Arap W. Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J Biol Chem 283(43):29447-60, 10/2008. PMID: 18718906.
45. Arap W. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 359(2):200-1, 7/2008. PMID: 18618944.
46. Ozawa MG, Zurita A, Dias-Neto E, Nunes DN, Sidman RL, Gelovani JG, Arap W, Pasqualini R. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med 18(4):126-32, 5/2008. PMID: 18555185.
47. Hajitou A, Lev DC, Hannay J, Korchin B, Staquicini FI, Soghomonyan S, Alauddin MM, Benjamin RS, Pollock RE, Gelovani JG, Pasqualini R, Arap W. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A 105(11):4471-6, 3/2008. PMID: 18337507.
48. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH, March KL. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 102(1):77-85, 1/2008. PMID: 17967785.
49. Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W. The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor-binding site within neuropilin-1. Cancer Res 67(20):9623-9, 10/2007. PMID: 17942890.
50. Lahdenranta J, Sidman RL, Pasqualini R, Arap W. Treatment of hypoxia-induced retinopathy with targeted propapoptotic peptidomimetics in a mouse model of disease. FASEB J 21(12):3272-8, 10/2007. PMID: 17513561.
51. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, Pasqualini R, Arap W. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc 2(3):523-31, 3/2007. PMID: 17406616.
52. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, Van Pelt CS, Tinkey PT, Behringer RR, Sidman RL, Arap W, Pasqualini R. Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A 104(11):4588-93, 3/2007. PMID: 17360568.
53. Soghomonyan S, Hajitou A, Rangel R, Pasqualini R, Arap W, Gelovani JG, Alauddin M. Molecular PET imaging of HSV1-tk reporter gene expression using 18F-FEAU. Nat Protoc 2(2):416-23, 2/2007. PMID: 17406603.
54. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA, Pasqualini R, Arap W. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 20(7):979-81, 5/2006. PMID: 16581960.
55. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC III, Restel BH, Ozawa MG, Moya CA, Rangel R, Sun Y, Zaoui K, Schmidt M, von Kalle C, Weitzman MD, Gelovani JG, Pasqualini R, Arap W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125(2):385-98, 4/2006. PMID: 16630824.
56. Kolonin MG, Bover L, Sun J, Zurita AJ, Do Kim-Anh, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 66(1):34-40, 1/2006. PMID: 16397212.
57. Souza GR, Christianson DR, Staquicini FI, Ozawa MG, Snyder EY, Sidman RL, Miller JH, Arap W, Pasqualini R. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci U S A 103(5):1215-20, 1/2006. PMID: 16434473.
58. Pentz RD, Cohen CB, Wicclair M, DeVita MA, Flamm AL, Youngner SJ, Hamric AB, McCabe MS, Glover J, Kittiko WJ, Kinlaw K, Keller J, Asch A, Kavanagh JJ, Arap W. Ethics guidelines for research with the recently dead. Nat Med 11(11):1145-9, 11/2005. PMID: 16270065.
59. Giordano RJ, Anobom CD, Cardó-Vila M, Kalil J, Valente AP, Pasqualini R, Almeida FC, Arap W. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol 12(10):1075-83, 10/2005. PMID: 16242650.
60. Marchiò S, Alfano M, Primo L, Gramaglia D, Butini L, Gennero L, De Vivo E, Arap W, Giacca M, Pasqualini R, Bussolino F. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 105(7):2802-11, 4/2005. PMID: 15591114.
61. Yao VJ, Ozawa MG, Trepel M, Arap W, McDonald DM, Pasqualini R. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 166(2):625-36, 2/2005. PMID: 15681844.
62. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6(3):275-84, 9/2004. PMID: 15380518.
63. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10(6):625-32, 6/2004. PMID: 15133506.
64. Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5(2):151-62, 2/2004. PMID: 14998491.
65. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 1/2004. PMID: 14744752.
66. Pasqualini R, Arap W. Hybridoma-free generation of monoclonal antibodies. Proc Natl Acad Sci U S A 101(1):257-9, 1/2004. PMID: 14688405.
67. Ellerby HM, Lee S, Ellerby LM, Chen S, Kiyota T, del Rio G, Sugihara G, Sun Y, Bredesen DE, Arap W, Pasqualini R. An artificially designed pore-forming protein with anti-tumor effects. J Biol Chem 278(37):35311-6, 9/2003. PMID: 12750379.
68. Cardó-Vila M, Arap W, Pasqualini R. Alpha v beta 5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol Cell 11(5):1151-62, 5/2003. PMID: 12769841.
69. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 33(1):20-6, 2/2003. PMID: 12613384.
70. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63, 1/2003. PMID: 12496764.
71. Kolonin MG, Pasqualini R, Arap W. Teratogenicity induced by targeting a placental immunoglobulin transporter. Proc Natl Acad Sci U S A 99(20):13055-60, 10/2002. PMID: 12242328.
72. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62(3):867-74, 2/2002. PMID: 11830545.
73. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121-7, 2/2002. PMID: 11821895.
74. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99(3):1527-31, 2/2002. PMID: 11830668.
75. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 7(11):1249-53, 11/2001. PMID: 11689892.
76. Trepel M, Arap W, Pasqualini R. Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Res 61(22):8110-2, 11/2001. PMID: 11719437.
77. Lahdenranta J, Pasqualini R, Schlingemann RO, Hagedorn M, Stallcup WB, Bucana CD, Sidman RL, Arap W. An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. Proc Natl Acad Sci U S A 98(18):10368-73, 8/2001. PMID: 11526242.
78. Tellier MC, Greco G, Klotman M, Mosoian A, Cara A, Arap W, Ruoslahti E, Pasqualini R, Schnapp LM. Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes. J Immunol 164(6):3236-45, 3/2000. PMID: 10706716.
79. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60(3):722-7, 2/2000. PMID: 10676659.
80. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5(9):1032-8, 9/1999. PMID: 10470080.
81. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17(8):768-74, 8/1999. PMID: 10429241.
82. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59(12):2869-74, 6/1999. PMID: 10383148.
83. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102(2):430-7, 7/1998. PMID: 9664085.
84. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349):377-80, 1/1998. PMID: 9430587.
85. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 55(9):1941-5, 5/1995. PMID: 7728764.
86. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55(6):1351-4, 3/1995. PMID: 7882335.

Invited Articles
1. Arap W, Trepel M, Zetter BR, Pasqualini R. Meeting report: innovations in prostate cancer research. Cancer Res 68(3):635-8, 2/2008. PMID: 18245458.
2. Trepel M, Pasqualini R, Arap W. Screening Phage-Display Peptide Libraries for Vascular Targeted Peptides. Methods Enzymol 445:83-106, 1/2008. PMID: 19022056.
3. Sato M, Pasqualini R, Arap W. Molecular targets on blood vessels for cancer therapies currently in clinical trials. Oncology 21(11):1346-52; discussion 1354-5, 1367, 1370 passim. rev., 10/2007. PMID: 18080618.
4. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 58(15):1622-54, 12/2006. PMID: 17123658.
5. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16(3):80-8, 4/2006. PMID: 16546688.
6. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 8(12):563-71, 12/2002. PMID: 12470989.
7. Pasqualini R, Arap W. Translation of vascular diversity into targeted therapeutics. Ann Hematol 81(Suppl 2):S66-7, 9/2002. PMID: 12611081.
8. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6(3):399-404, 6/2002. PMID: 12023122.
9. Arap W, Pasqualini R. In vivo screening: vascular maps. Nature Reviews Drug Discovery 1:174, 3/2002.
10. Arap W, Pasqualini R. The human vascular mapping project. Selection and utilization of molecules for tumor endothelial targeting. Haemostasis 31(Suppl 1):30-1, 12/2001. PMID: 11990470.
11. Kolonin MG, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 5(3):308-13, 6/2001. PMID: 11479123.
12. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10(6):560-5, 11/1998. PMID: 9818236.

Editorials
1. Arap W, Pasqualini R. Engineered embryonic endothelial progenitor cells as therapeutic Trojan horses. Cancer Cell 5(5):406-8, 5/2004. PMID: 15144946.
2. Pasqualini R, Barbas CF III, Arap W. Vessel maneuvers: zinc fingers promote angiogenesis. Nat Med 8(12):1353-4, 12/2002. PMID: 12457173.
3. Pasqualini R, McDonald DM, Arap W. Vascular targeting and antigen presentation. Nat Immunol 2(7):567-8, 7/2001. PMID: 11429533.

Book Chapters
1. Eckhardt BL, Smith TL, Anderson RL, Arap W, Pasqualini R. Stromal-derived factors that dictate organ-specific metastasis. In: Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press: New York. In Press.
2. Arap W, Pasqualini R. Mapping human vasculature. In: Protein Discovery Technologies, Principles, Methods and Applications. Marcel Dekker/CRC Press: Boca Raton, FL, 99-112, 2009.
3. Zurita AJ, Arap W, Pasqualini R. Molecular characterization of the endothelium: A phage display perspective the endothelium. In: In: A Comprehensive Reference, The Endothelial Cell as Input-Output Device/Output/Proteome. Ed(s) Ed. Aird WC. Marcel Dekker, Inc., 898-908, 2007.
4. Trepel M, Arap W, Pasqualini R. Selection, isolation, and identification of targeting peptides for ligand-directed gene delivery. In: Gene Transfer, Delivery, and Expression of DNA and RNA: A Laboratory Manual. Ed(s) Friedman & Rossi. Cold Spring Harbor Laboratory Press: New York, NY, 359-369, 2007.
5. Christianson DR, Ozawa MG, Pasqualini R, Arap W. Techniques to decipher molecular diversity by phage display. In: Cardiovascular Proteomics book in Methods in Molecular Biology. 357. Humana Press, 385-406, 2006. ISBN: 17172704.
6. Lahdenranta J, Arap W, Pasqualini R. The use of proteomics to map phenotypic heterogeneity of the endothelium. In: Endothelial Cells in Health and Disease. Ed(s) Aird W.C. Marcel Dekker Inc, 105-119, 2005.
7. Kolonin MG, Pasqualini R, Arap W. Mapping human vascular heterogeneity by in vivo phage display. In: Genetics of Angiogenesis. Ed(s) James B. Hoying. BIOS Scientific Publishers Ltd,: Oxford, 181-7, 2003.
8. Vidal C, Cardó-Vila M, Lahdenranta J, Arap W, Pasqualini R. Targeting blood vessels in vivo by using phage display libraries. In: Targeted Therapy for Cancer. Ed(s) Syrigos, Harrington, 250-255, 2003.
9. Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. In: The Encyclopedia of Cancer, 2nd. Ed(s) Joseph R. Bertino. Academic Press Inc. New Brunswick, NJ, 501-7, 2002.
10. Pasqualini R, Arap W, Rajotte D, and Ruoslahti E. In vivo selection of phage-display libraries. In: Phage Display: A Laboratory Manual. Ed(s) In: C. F. Barbas, III, D. R. Burton, J. K. Scott, and G. J. Silverman (eds.). Cold Spring Harbor Laboratory Press: New York, 1-24, 2001.

Books (edited and written)
1. Imaging the Tumor Microenvironment. Springer - Cancer Research, 2012.
2. Pasqualini R. Ed(s) Pasqualini R. Tissue-specific vascular endothelial signals and vector targeting, Part B. In: Advances in Genetics. Series Ed(s) SF Goodwin, JC Dunlap, T Friedmann. 69. Academic Press is an imprint of Elsevier: London, 2010.

Letters to the Editor
1. Kontoyiannis DP, Pasqualini R, Arap W. Aminopeptidase N inhibitors and SARS. Lancet 361(9368):1558, 5/2003. PMID: 12737884.

Last updated: 3/12/2013